BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/24/2024 2:54:45 AM | Browse: 143 | Download: 632
 |
Received |
|
2024-06-11 14:29 |
|
Peer-Review Started |
|
2024-06-11 14:29 |
|
First Decision by Editorial Office Director |
|
2024-07-25 02:24 |
|
Return for Revision |
|
2024-07-25 02:24 |
|
Revised |
|
2024-07-25 20:28 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-07-31 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-07-31 08:51 |
|
Articles in Press |
|
2024-07-31 08:51 |
|
Edit the Manuscript by Language Editor |
|
2024-08-13 02:17 |
|
Typeset the Manuscript |
|
2024-08-22 14:11 |
|
Publish the Manuscript Online |
|
2024-09-24 02:54 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Editorial |
| Article Title |
Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Basma M E Mohamed and Mohamed E A Abdelrahim |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mohamed E A Abdelrahim, PhD, Professor, Department of Clinical Pharmacy, Faculty of pharmacy, Beni-suef University, Beni suef 23343, Egypt. mohamed.abdelrahim@pharm.bsu.edu.eg |
| Key Words |
Idiopathic pulmonary fibrosis; Pirfenidone; Pirfenidone anti-inflammatory mechanism; Pirfenidone anti-fibrotic activity |
| Core Tip |
Pirfenidone is commonly used to treat idiopathic pulmonary fibrosis (IPF) in its early stages, but it has also demonstrated a notable impact on the disease in its advanced stages. In individuals with IPF who had substantial deterioration of their lung function, pirfenidone had a similar degree of efficacy. Pirfenidone appears to be safe when given to patients with advanced IPF, and it has a favorable benefit-risk profile, making it an appropriate treatment option for patients with idiopathic pulmonary fibrosis. |
| Publish Date |
2024-09-24 02:54 |
| Citation |
Mohamed BME, Abdelrahim MEA. Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression. World J Clin Cases 2024; 12(32): 6538-6542 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i32/6538.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i32.6538 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
